Correction: Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells (J. Exp. Med 2023 213, 13, 10.1084/jem.20151665);Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells

Journal of Experimental Medicine

Volumn 213, Issue 13, 2016, Pages 2967-2988

  Chan, Tze Sian ^a,b   Hsu, Chung Chi ^a,c   Pai, Vincent C ^a,c   Liao, Wen Ying ^c   Huang, Shenq Shyang ^d   Tan, Kok Tong ^e   Yen, Chia Jui ^f   Hsu, Shu Ching ^c   Chen, Wei Yu ^b   Shan, Yan Shen ^f   Li, Chi Rong ^a   Lee, Michael T ^g   Jiang, Kuan Ying ^c   Chu, Jui Mei ^c   Lien, Gi Shih ^a,b   Weaver, Valerie M ^h   Tsai, Kelvin K ^a,c,f  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^e TUNGS' TAICHUNG METROHARBOR HOSPITAL   (Taiwan)

^f NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^g KUN SHAN UNIVERSITY   (Taiwan)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 BROMOPHENYL) 3 (2 HYDROXY 4 NITROPHENYL)UREA; CHEMOKINE; CHEMOKINE RECEPTOR CXCR2; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GRANULOCYTE CHEMOTACTIC PROTEIN 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PACLITAXEL; STAT1 PROTEIN; STAT1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER PATIENT; CARCINOGENESIS; CARCINOMA ASSOCIATED FIBROBLAST; CARCINOMA CELL; CELL EXPANSION; CELL INFILTRATION; CELL INTERACTION; CELL POPULATION; CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LOW DRUG DOSE; MACROPHAGE; MAXIMUM TOLERATED DOSE; METASTASIS; MOUSE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN SECRETION; STROMA; TREATMENT RESPONSE; TUMOR INITIATING CELL; TUMOR INVASION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; BREAST NEOPLASMS; MCF-7 CELL LINE; METABOLISM; METRONOMIC DRUG ADMINISTRATION; PATHOLOGY; STROMA CELL; U-937 CELL LINE;

ADMINISTRATION, METRONOMIC; BREAST NEOPLASMS; FEMALE; FIBROBLASTS; HUMANS; MCF-7 CELLS; NF-KAPPA B; RECEPTORS, INTERLEUKIN-8B; STAT1 TRANSCRIPTION FACTOR; STROMAL CELLS; U937 CELLS;

EID: 85008433322     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.2015166506142023c     Document Type: Erratum

References (72)

1. Al-Hajj, M., M.S. Wicha, A. Benito-Hernandez, S.J. Morrison, and M.F. Clarke. 2003. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA. 100:3983-3988. http://dx.doi.org/10.1073/pnas.0530291100
2. Ali, S., and G. Lazennec. 2007. Chemokines: novel targets for breast cancer metastasis. Cancer Metastasis Rev. 26:401-420. http://dx.doi.org/10.1007/s10555-007-9073-z
3. Arensman, M.D., A.N. Kovochich, R.M. Kulikauskas, A.R. Lay, P.T. Yang, X. Li, T. Donahue, M.B. Major, R.T. Moon, A.J. Chien, and D.W. Dawson. 2014. WNT7B mediates autocrine Wnt/β-catenin signaling and anchorage-independent growth in pancreatic adenocarcinoma. Oncogene. 33:899-908. http://dx.doi.org/10.1038/onc.2013.23
4. Beck, B., G. Driessens, S. Goossens, K.K. Youssef, A. Kuchnio, A. Caauwe, P.A. Sotiropoulou, S. Loges, G. Lapouge, A. Candi, et al. 2011. A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature. 478:399-403. http://dx.doi.org/10.1038/nature10525
5. Bertolini, F., S. Paul, P. Mancuso, S. Monestiroli, A. Gobbi, Y. Shaked, and R.S. Kerbel. 2003. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 63:4342-4346.
6. Bocci, G., K.C. Nicolaou, and R.S. Kerbel. 2002. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res. 62:6938-6943.
7. Bocci, G., G. Francia, S. Man, J. Lawler, and R.S. Kerbel. 2003. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc. Natl. Acad. Sci. USA. 100:12917-12922. http://dx.doi.org/10.1073/pnas.2135406100
8. Bruchard, M., G. Mignot, V. Derangère, F. Chalmin, A. Chevriaux, F. Végran, W. Boireau, B. Simon, B. Ryffel, J.L. Connat, et al. 2013. Chemotherapytriggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat. Med. 19:57-64. http://dx.doi.org/10.1038/nm.2999
9. Calabrese, C., H. Poppleton, M. Kocak, T.L. Hogg, C. Fuller, B. Hamner, E.Y. Oh, M.W. Gaber, D. Finklestein, M. Allen, et al. 2007. A perivascular niche for brain tumor stem cells. Cancer Cell. 11:69-82. http://dx.doi.org/10.1016/j.ccr.2006.11.020
10. Chen, W.J., C.C. Ho, Y.L. Chang, H.Y. Chen, C.A. Lin, T.Y. Ling, S.L. Yu, S.S. Yuan, Y.J. Chen, C.Y. Lin, et al. 2014. Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling. Nat. Commun. 5:3472.
11. Cheng, J.D., R.L. Dunbrack Jr., M. Valianou, A. Rogatko, R.K. Alpaugh, and L.M. Weiner. 2002. Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res. 62:4767-4772.
12. Creighton, C.J., X. Li, M. Landis, J.M. Dixon, V.M. Neumeister, A. Sjolund, D.L. Rimm, H. Wong, A. Rodriguez, J.I. Herschkowitz, et al. 2009. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc. Natl. Acad. Sci. USA. 106:13820-13825. http://dx.doi.org/10.1073/pnas.0905718106
13. Daenen, L.G., J.M. Roodhart, M. van Amersfoort, M. Dehnad, W. Roessingh, L.H. Ulfman, P.W. Derksen, and E.E. Voest. 2011. Chemotherapy enhances metastasis formation via VEG FR-1-expressing endothelial cells. Cancer Res. 71:6976-6985. http://dx.doi.org/10.1158/0008-5472.CAN-11-0627
14. Dupuis, S., C. Dargemont, C. Fieschi, N. Thomassin, S. Rosenzweig, J. Harris, S.M. Holland, R.D. Schreiber, and J.L. Casanova. 2001. Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science. 293:300-303. http://dx.doi.org/10.1126/science.1061154
15. Erez, N., M. Truitt, P. Olson, S.T. Arron, and D. Hanahan. 2010. Cancerassociated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-κB-dependent manner. Cancer Cell. 17:135-147. http://dx.doi.org/10.1016/j.ccr.2009.12.041
16. Finak, G., N. Bertos, F. Pepin, S. Sadekova, M. Souleimanova, H. Zhao, H. Chen, G. Omeroglu, S. Meterissian, A. Omeroglu, et al. 2008. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 14:518-527. http://dx.doi.org/10.1038/nm1764
17. Fogli, S., R. Danesi, A. Gennari, S. Donati, P.F. Conte, and M. Del Tacca. 2002. Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. Ann. Oncol. 13:919-927. http://dx.doi.org/10.1093/annonc/mdf164
18. Folkins, C., S. Man, P. Xu, Y. Shaked, D.J. Hicklin, and R.S. Kerbel. 2007. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res. 67:3560-3564. http://dx.doi.org/10.1158/0008-5472.CAN-06-4238
19. + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56:641-648. http://dx.doi.org/10.1007/s00262-006-0225-8
20. Ginestier, C., M.H. Hur, E. Charafe-Jauffret, F. Monville, J. Dutcher, M. Brown, J. Jacquemier, P. Viens, C.G. Kleer, S. Liu, et al. 2007. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 1:555-567. http://dx.doi.org/10.1016/j.stem.2007.08.014
21. Gingis-Velitski, S., D. Loven, L. Benayoun, M. Munster, R. Bril, T. Voloshin, D. Alishekevitz, F. Bertolini, and Y. Shaked. 2011. Host response to shortterm, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice. Cancer Res. 71:6986-6996. http://dx.doi.org/10.1158/0008-5472.CAN-11-0629
22. Goetz, J.G., S. Minguet, I. Navarro-Lérida, J.J. Lazcano, R. Samaniego, E. Calvo, M. Tello, T. Osteso-Ibáñez, T. Pellinen, A. Echarri, et al. 2011. Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell. 146:148-163. http://dx.doi.org/10.1016/j.cell.2011.05.040
23. Grunewald, R., H. Kantarjian, M. Du, K. Faucher, P. Tarassoff, and W. Plunkett. 1992. Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J. Clin. Oncol. 10:406-413.
24. Hasnis, E., D. Alishekevitz, S. Gingis-Veltski, R. Bril, E. Fremder, T. Voloshin, Z. Raviv, A. Karban, and Y. Shaked. 2014. Anti-Bv8 antibody and metronomic gemcitabine improve pancreatic adenocarcinoma treatment outcome following weekly gemcitabine therapy. Neoplasia. 16:501-510. http://dx.doi.org/10.1016/j.neo.2014.05.011
25. Hidalgo, M., F. Amant, A.V. Biankin, E. Budinská, A.T. Byrne, C. Caldas, R.B. Clarke, S. de Jong, J. Jonkers, G.M. Mælandsmo, et al. 2014. Patientderived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 4:998-1013. http://dx.doi.org/10.1158/2159-8290.CD-14-0001
26. Hughes, R., B.Z. Qian, C. Rowan, M. Muthana, I. Keklikoglou, O.C. Olson, S. Tazzyman, S. Danson, C. Addison, M. Clemons, et al. 2015. Perivascular M2 macrophages stimulate tumor relapse after chemotherapy. Cancer Res. 75:3479-3491. http://dx.doi.org/10.1158/0008-5472.CAN-14-3587
27. Iliopoulos, D., H.A. Hirsch, G. Wang, and K. Struhl. 2011. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc. Natl. Acad. Sci. USA. 108:1397-1402. http://dx.doi.org/10.1073/pnas.1018898108
28. Jesnowski, R., D. Fürst, J. Ringel, Y. Chen, A. Schrödel, J. Kleeff, A. Kolb, W.D. Schareck, and M. Löhr. 2005. Immortalization of pancreatic stellate cells as an in vitro model of pancreatic fibrosis: deactivation is induced by matrigel and N-acetylcysteine. Lab. Invest. 85:1276-1291. http://dx.doi.org/10.1038/labinvest.3700329
29. Jung, J.H., S.J. Lee, J. Kim, S. Lee, H.J. Sung, J. An, Y. Park, and B.S. Kim. 2015. CXCR2 and its related ligands play a novel role in supporting the pluripotency and proliferation of human pluripotent stem cells. Stem Cells Dev. 24:948-961. http://dx.doi.org/10.1089/scd.2014.0381
30. Kalluri, R., and M. Zeisberg. 2006. Fibroblasts in cancer. Nat. Rev. Cancer. 6:392-401. http://dx.doi.org/10.1038/nrc1877
31. Karnoub, A.E., A.B. Dash, A.P. Vo, A. Sullivan, M.W. Brooks, G.W. Bell, A.L. Richardson, K. Polyak, R. Tubo, and R.A. Weinberg. 2007. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 449:557-563. http://dx.doi.org/10.1038/nature06188
32. Kerbel, R.S., and A. Grothey. 2015. Gastrointestinal cancer: Rationale for metronomic chemotherapy in phase III trials. Nat. Rev. Clin. Oncol. 12:313-314. http://dx.doi.org/10.1038/nrclinonc.2015.89
33. Kerbel, R.S., and B.A. Kamen. 2004. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer. 4:423-436. http://dx.doi.org/10.1038/nrc1369
34. Korkaya, H., S. Liu, and M.S. Wicha. 2011. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J. Clin. Invest. 121:3804-3809. http://dx.doi.org/10.1172/JCI57099
35. Korkaya, H., G.I. Kim, A. Davis, F. Malik, N.L. Henry, S. Ithimakin, A.A. Quraishi, N. Tawakkol, R. D'Angelo, A.K. Paulson, et al. 2012. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol. Cell. 47:570-584. http://dx.doi.org/10.1016/j.molcel.2012.06.014
36. Kuperwasser, C., T. Chavarria, M. Wu, G. Magrane, J.W. Gray, L. Carey, A. Richardson, and R.A. Weinberg. 2004. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc. Natl. Acad. Sci. USA. 101:4966-4971. http://dx.doi.org/10.1073/pnas.0401064101
37. Lawson, D.A., N.R. Bhakta, K. Kessenbrock, K.D. Prummel, Y. Yu, K. Takai, A. Zhou, H. Eyob, S. Balakrishnan, C.Y. Wang, et al. 2015. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature. 526:131-135. http://dx.doi.org/10.1038/nature15260
38. Lee, G.Y., P.A. Kenny, E.H. Lee, and M.J. Bissell. 2007. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat. Methods. 4:359-365. http://dx.doi.org/10.1038/nmeth1015
39. Levental, K.R., H. Yu, L. Kass, J.N. Lakins, M. Egeblad, J.T. Erler, S.F. Fong, K. Csiszar, A. Giaccia, W. Weninger, et al. 2009. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 139:891-906. http://dx.doi.org/10.1016/j.cell.2009.10.027
40. Li, C., D.G. Heidt, P. Dalerba, C.F. Burant, L. Zhang, V. Adsay, M. Wicha, M.F. Clarke, and D.M. Simeone. 2007. Identification of pancreatic cancer stem cells. Cancer Res. 67:1030-1037. http://dx.doi.org/10.1158/0008-5472.CAN-06-2030
41. Li, X., M.T. Lewis, J. Huang, C. Gutierrez, C.K. Osborne, M.F. Wu, S.G. Hilsenbeck, A. Pavlick, X. Zhang, G.C. Chamness, et al. 2008. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer Inst. 100:672-679. http://dx.doi.org/10.1093/jnci/djn123
42. Liotta, L.A., and E.C. Kohn. 2001. The microenvironment of the tumour-host interface. Nature. 411:375-379. http://dx.doi.org/10.1038/35077241
43. Liu, S., C. Ginestier, S.J. Ou, S.G. Clouthier, S.H. Patel, F. Monville, H. Korkaya, A. Heath, J. Dutcher, C.G. Kleer, et al. 2011. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res. 71:614-624. http://dx.doi.org/10.1158/0008-5472.CAN-10-0538
44. Liu, S., Y. Cong, D. Wang, Y. Sun, L. Deng, Y. Liu, R. Martin-Trevino, L. Shang, S.P. McDermott, M.D. Landis, et al. 2014. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Rep. 2:78-91. http://dx.doi.org/10.1016/j.stemcr.2013.11.009
45. Lotti, F., A.M. Jarrar, R.K. Pai, M. Hitomi, J. Lathia, A. Mace, G.A. Gantt Jr., K. Sukhdeo, J. DeVecchio, A. Vasanji, et al. 2013. Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A. J. Exp. Med. 210:2851-2872. http://dx.doi.org/10.1084/jem.20131195
46. Loven, D., E. Hasnis, F. Bertolini, and Y. Shaked. 2013. Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer. Drug Discov. Today. 18:193-201. http://dx.doi.org/10.1016/j.drudis.2012.07.015
47. +25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 105:2862-2868. http://dx.doi.org/10.1182/blood-2004-06-2410
48. McAllister, S.S., and R.A. Weinberg. 2014. The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat. Cell Biol. 16:717-727. http://dx.doi.org/10.1038/ncb3015
49. Nakasone, E.S., H.A. Askautrud, T. Kees, J.H. Park, V. Plaks, A.J. Ewald, M. Fein, M.G. Rasch, Y.X. Tan, J. Qiu, et al. 2012. Imaging tumorstroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell. 21:488-503. http://dx.doi.org/10.1016/j.ccr.2012.02.017
50. Orimo, A., P.B. Gupta, D.C. Sgroi, F. Arenzana-Seisdedos, T. Delaunay, R. Naeem, V.J. Carey, A.L. Richardson, and R.A. Weinberg. 2005. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 121:335-348. http://dx.doi.org/10.1016/j.cell.2005.02.034
51. Pasquier, E., M. Kavallaris, and N. André. 2010. Metronomic chemotherapy: new rationale for new directions. Nat. Rev. Clin. Oncol. 7:455-465. http://dx.doi.org/10.1038/nrclinonc.2010.82
52. Rudnick, J.A., L.M. Arendt, I. Klebba, J.W. Hinds, V. Iyer, P.B. Gupta, S.P. Naber, and C. Kuperwasser. 2011. Functional heterogeneity of breast fibroblasts is defined by a prostaglandin secretory phenotype that promotes expansion of cancer-stem like cells. PLoS One. 6:e24605. http://dx.doi.org/10.1371/journal.pone.0024605
53. Seifert, L., G. Werba, S. Tiwari, N.N. Giao Ly, S. Alothman, D. Alqunaibit, A. Avanzi, R. Barilla, D. Daley, S.H. Greco, et al. 2016. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. Nature. 532:245-249. http://dx.doi.org/10.1038/nature17403
54. Serebriiskii, I., R. Castelló-Cros, A. Lamb, E.A. Golemis, and E. Cukierman. 2008. Fibroblast-derived 3D matrix differentially regulates the growth and drug-responsiveness of human cancer cells. Matrix Biol. 27:573-585. http://dx.doi.org/10.1016/j.matbio.2008.02.008
55. Shaked, Y., E. Henke, J.M. Roodhart, P. Mancuso, M.H. Langenberg, M. Colleoni, L.G. Daenen, S. Man, P. Xu, U. Emmenegger, et al. 2008. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell. 14:263-273. http://dx.doi.org/10.1016/j.ccr.2008.08.001
56. Sherman, M.H., R.T. Yu, D.D. Engle, N. Ding, A.R. Atkins, H. Tiriac, E.A. Collisson, F. Connor, T. Van Dyke, S. Kozlov, et al. 2014. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell. 159:80-93. http://dx.doi.org/10.1016/j.cell.2014.08.007
57. Shiao, S.L., and L.M. Coussens. 2010. The tumor-immune microenvironment and response to radiation therapy. J. Mammary Gland Biol. Neoplasia. 15:411-421. http://dx.doi.org/10.1007/s10911-010-9194-9
58. Shree, T., O.C. Olson, B.T. Elie, J.C. Kester, A.L. Garfall, K. Simpson, K.M. Bell-McGuinn, E.C. Zabor, E. Brogi, and J.A. Joyce. 2011. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev. 25:2465-2479. http://dx.doi.org/10.1101/gad.180331.111
59. Sonnenberg, M., H. van der Kuip, S. Haubeis, P. Fritz, W. Schroth, G. Friedel, W. Simon, T.E. Mürdter, and W.E. Aulitzky. 2008. Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast. BMC Cancer. 8:364. http://dx.doi.org/10.1186/1471-2407-8-364
60. Struck, R.F., D.S. Alberts, K. Horne, J.G. Phillips, Y.M. Peng, and D.J. Roe. 1987. Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial. Cancer Res. 47:2723-2726.
61. Sun, Y., J. Campisi, C. Higano, T.M. Beer, P. Porter, I. Coleman, L. True, and P.S. Nelson. 2012. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat. Med. 18:1359-1368. http://dx.doi.org/10.1038/nm.2890
62. Tanaka, H., H. Matsushima, A. Nishibu, B.E. Clausen, and A. Takashima. 2009. Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. Cancer Res. 69:6987-6994. http://dx.doi.org/10.1158/0008-5472.CAN-09-1106
63. te Poele, R.H., A.L. Okorokov, L. Jardine, J. Cummings, and S.P. Joel. 2002. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res. 62:1876-1883.
64. Tsai, K.K., E.Y. Chuang, J.B. Little, and Z.M. Yuan. 2005. Cellular mechanisms for low-dose ionizing radiation-induced perturbation of the breast tissue microenvironment. Cancer Res. 65:6734-6744. http://dx.doi.org/10.1158/0008-5472.CAN-05-0703
65. Tsuyada, A., A. Chow, J. Wu, G. Somlo, P. Chu, S. Loera, T. Luu, A.X. Li, X. Wu, W. Ye, et al. 2012. CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res. 72:2768-2779. http://dx.doi.org/10.1158/0008-5472.CAN-11-3567
66. Twelves, C.J., N.A. Dobbs, M. Aldhous, P.G. Harper, R.D. Rubens, and M.A. Richards. 1991. Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer. Cancer Chemother. Pharmacol. 28:302-307.
67. Vermeulen, L., F. De Sousa E Melo, M. van der Heijden, K. Cameron, J.H. de Jong, T. Borovski, J.B. Tuynman, M. Todaro, C. Merz, H. Rodermond, et al. 2010. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 12:468-476. http://dx.doi.org/10.1038/ncb2048
68. Visvader, J.E., and G.J. Lindeman. 2008. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer. 8:755-768. http://dx.doi.org/10.1038/nrc2499
69. Voloshin, T., D. Alishekevitz, L. Kaneti, V. Miller, E. Isakov, I. Kaplanov, E. Voronov, E. Fremder, M. Benhar, M. Machluf, et al. 2015. Blocking IL1β pathway following paclitaxel chemotherapy slightly inhibits primary tumor growth but promotes spontaneous metastasis. Mol. Cancer Ther. 14:1385-1394. http://dx.doi.org/10.1158/1535-7163.MCT-14-0969
70. Wang, W.Y., C.C. Hsu, T.Y. Wang, C.R. Li, Y.C. Hou, J.M. Chu, C.T. Lee, M.S. Liu, J.J. Su, K.Y. Jian, et al. 2013. A gene expression signature of epithelial tubulogenesis and a role for ASPM in pancreatic tumor progression. Gastroenterology. 145:1110-1120. http://dx.doi.org/10.1053/j.gastro.2013.07.040
71. Yamauchi, K., M. Yang, K. Hayashi, P. Jiang, N. Yamamoto, H. Tsuchiya, K. Tomita, A.R. Moossa, M. Bouvet, and R.M. Hoffman. 2008. Induction of cancer metastasis by cyclophosphamide pretreatment of host mice: an opposite effect of chemotherapy. Cancer Res. 68:516-520. http://dx.doi.org/10.1158/0008-5472.CAN-07-3063
72. Zhang, M., A. Tsimelzon, C.H. Chang, C. Fan, A. Wolff, C.M. Perou, S.G. Hilsenbeck, and J.M. Rosen. 2015. Intratumoral heterogeneity in a Trp53-null mouse model of human breast cancer. Cancer Discov. 5:520-533. http://dx.doi.org/10.1158/2159-8290.CD-14-1101